The Funding Will Accelerate Development of an Intramuscular Formulation of ENA-001, a Novel Agnostic Respiratory Stimulant, for the Potential Treatment of Community Drug Overdose and as a Medical Countermeasure for Mass Casualty Events. The Funding Supports Development of an Intramuscular ENA-001 From Pre-Clinical Toxicology Through Filing for Approval in the United States
Read MoreLatest milestone brings the Selux Next-Generation Phenotyping (NGP) platform one step closer to impacting patient care with same-shift Antibiotic Susceptibility Testing (AST).
Read More